Otonomy to Participate in the H.C. Wainwright Global Investment Conference

Rhea-AI Summary

Otonomy, Inc. (Nasdaq: OTIC) announced its participation in the H.C. Wainwright Global Investment Conference, set to take place on May 24, 2022. A pre-recorded presentation by the management team will be accessible at 7 a.m. ET / 4 a.m. PT on the conference website. Additionally, a link will be available on Otonomy's Events page. The company specializes in innovative therapeutics for neurotology, particularly in addressing hearing loss and tinnitus through advanced drug delivery technology.

News Market Reaction – OTIC

-5.56%

-5.56% Session move

In the trading session that priced this news, OTIC declined 5.56%, reflecting a notable negative market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, May 18, 2022 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq: OTIC), a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology, today announced its participation in the H.C. Wainwright Global Investment Conference (Hybrid Conference). A pre-recorded company presentation by the Otonomy management team will be available on the conference website beginning at 7 a.m. ET / 4 a.m. PT on May 24, 2022.

A link to the presentation will also become available at the same time through the Events page of the company's website (www.otonomy.com).

About Otonomy

Otonomy is a biopharmaceutical company dedicated to the development of innovative therapeutics for neurotology. The company pioneered the application of drug delivery technology to the ear in order to develop products that achieve sustained drug exposure from a single local administration. This approach is covered by a broad patent estate and is being utilized to develop a pipeline of products addressing important unmet medical needs with a focus on hearing loss and tinnitus. For additional information please visit www.otonomy.com.

Contacts:

Media Inquiries
Spectrum Science
Lauren Benton
Senior Account Executive
212.899.9731
lbenton@spectrumscience.com

Investor Inquiries:
ICR Westwicke
Robert H. Uhl
Managing Director
858.356.5932
robert.uhl@westwicke.com

FAQ

When will Otonomy's presentation be available at the H.C. Wainwright Global Investment Conference?

Otonomy's pre-recorded presentation will be available on May 24, 2022, starting at 7 a.m. ET / 4 a.m. PT.

What is the ticker symbol for Otonomy?

The ticker symbol for Otonomy is OTIC.

What is the focus of Otonomy's therapeutics?

Otonomy focuses on innovative therapeutics for neurotology, primarily targeting hearing loss and tinnitus.

Where can I find the link to Otonomy's conference presentation?

The link to Otonomy's conference presentation will be available on their Events page on May 24, 2022.

What technology does Otonomy use for drug delivery?

Otonomy utilizes advanced drug delivery technology specifically designed for the ear to improve sustained drug exposure.